Opzelura (ruxolitinib) is now the first alternative to steroid drugs for vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million people in the US.

Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

If approved, Opzelura would provide an alternative to steroid drugs currently used to treat vitiligo, a chronic autoimmune disease that causes depigmentation of skin and affects around 1.5 million ...

Opzelura, that came out two years ago has changed that. “About two-thirds of patients are seeing at least 75% improvement in the vitiligo on the face, and that’s just the first time we’ve ...

Others question whether vitiligo should be celebrated rather than masked or corrected. Ruxolitinib (brand name Opzelura) must be prescribed by a doctor because the treatment requires monitoring.

and Opzelura, a topical cream for atopic dermatitis and vitiligo. Additionally, it has some promising candidates in the pipeline, including a CDK2 inhibitor for advanced solid tumors. The company ...